Sarah Cannon Cancer Center

Sarah Cannon is the cancer enterprise of HCA Healthcare, providing integrated cancer services from wellness and diagnosis to treatment and research. As a leading global clinical research organization, it specializes in phase 1-4 clinical trials and has been instrumental in the development of the majority of FDA-approved cancer therapies over the last decade. The organization operates a network of strategic sites across the United States and United Kingdom, offering patients access to innovative treatments close to home. Sarah Cannon's expertise spans drug development, blood and marrow transplantation, and personalized medicine through molecular profiling. In 2022, it expanded its reach through a joint venture with McKesson Corporation's US Oncology Research.